Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus Chemotherapy for Peritoneal Mesothelioma
NCT05001880Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2022
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in peritoneal mesothelioma, sponsored by National Cancer Institute. Started Mar 2022; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
peritoneal mesothelioma
Beyond the preview
Go deeper on NCT05001880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05001880.